STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Axsome Therapeutics, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.

Key transaction details:

  • Securities acquired through employee stock option exercise on June 20, 2025
  • Payment made via broker payment for cashless exercise
  • Total shares outstanding: 49,236,365
  • Planned sale date: June 20, 2025

The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.

Positive

  • None.

Negative

  • Insider Hunter R. Murdock has sold a total of 22,500 shares over three consecutive days (June 16-18, 2025) for approximately $2.28M, followed by another planned sale of 7,500 shares, indicating consistent selling pressure from management

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many AXSM shares were sold by Hunter R. Murdock in June 2025?

According to the Form 144 filing, Hunter R. Murdock sold three batches of 7,500 shares each on June 16, 17, and 18, 2025, totaling 22,500 shares. Additionally, there is a proposed sale of another 7,500 shares with an approximate sale date of June 20, 2025.

What was the total value of AXSM shares sold by Hunter Murdock in mid-June 2025?

The total gross proceeds from Hunter Murdock's sales were: $768,154 (June 16), $751,975 (June 17), and $756,729 (June 18), totaling $2,276,858 for the three transactions.

How did Hunter Murdock acquire the AXSM shares being sold?

The Form 144 indicates that the shares were acquired through an Employee Stock Option Exercise on June 20, 2025, with payment made through a Broker Payment for Cashless Exercise.

What is the total number of outstanding AXSM shares according to the June 2025 Form 144?

According to the Form 144 filing, Axsome Therapeutics had 49,236,365 shares outstanding at the time of the filing.

Through which broker is Hunter Murdock selling AXSM shares?

The shares are being sold through Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake TX 76262.
Axsome Therapeut

NASDAQ:AXSM

AXSM Rankings

AXSM Latest News

AXSM Latest SEC Filings

AXSM Stock Data

7.53B
41.82M
15.87%
77.48%
7.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK